title: Letter to the editor concerning the rationale and design of the X-VERT trial by Ezekowitz et al.
authors: Cardica Intensive Care Unit, Institute of Cardiology, Warsaw, Poland. Electronic address: mzaleska@ikard.pl.
authors: Marta
authors: M
authors: Załęska-Kocięcka
authors: Cardica Intensive Care Unit, Institute of Cardiology, Warsaw, Poland.
authors: Jannina
authors: J
authors: Stępińska
mesh_terms: D001281:Atrial Fibrillation / Q000628:therapy*; D004554:Electric Countershock; D004617:Embolism / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage*; D014812:Vitamin K / Q000037:antagonists & inhibitors*
chemical_list: D009025:Morpholines; D013876:Thiophenes; D014812:Vitamin K